Pharmanet Collaborates with the Cancer Immunotherapy Trials Network
Product News Jun 13, 2011
PharmaNet Development Group, Inc., has announced that it is collaborating with the Cancer Immunotherapy Trials Network (CITN), a premier network of clinical investigators, institutions and thought leaders in the area of cancer immunotherapy and vaccines, in order to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.
“We are thrilled to collaborate with the Cancer Immunotherapy Trials Network multi-investigator team,” commented Anthony Maida, PhD, MA, MBA, Vice President, Clinical Research and General Manager, Oncology.
Maida continued, “The association allows us to identify oncology centers of excellence and thought leaders to collaborate on the development of cutting-edge therapeutics.”
PharmaNet has been conducting clinical studies for innovative oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments.
The Company has extensive experience in the development of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types.
Two hundred local, regional and global oncology clinical trials have been awarded to PharmaNet in the past five years, including eleven registration programs, seven which resulted in NDA/MAA approvals.
PharmaNet’s focus on the development of immunotherapies and cancer vaccines is based on a core team of immunotherapy experts and partnerships to support this initiative.
“Clinical development of immunotherapies and cancer vaccines requires a special understanding of the mechanism of action and a different approach than traditional cancer therapies,” Dr. Maida added. “We are working with clients to address the unique methodologies needed to evaluate efficacy and safety of this class of innovative therapeutics.”